ArticleJournal of cachexia, sarcopenia and muscle2025
The Predictive Power of the Cystatin C-Creatinine Score in Assessing Frailty.
Article in Journal of cachexia, sarcopenia and muscle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Creatinine-to-Cystatin C Ratio Combined with FIB-4 and ELF for Noninvasive Fibrosis Assessment in MASLD.International journal of molecular sciences · 2025Article
- The Predictive Power of the Cystatin C-Creatinine Score in Assessing Frailty.Journal of cachexia, sarcopenia and muscle · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundAs the global population ages, identifying reliable biomarkers to predict frailty and mortality is critical for early intervention. This study aims to construct a valuable biomarker and evaluate its predictive performance in assessing frailty and all-cause mortality.
methodsData from 3613 participants in the Health and Retirement Study (HRS) were used to construct the nomogram and main analysis, whereas data from the National Health and Nutrition Examination Survey were used to validate the robustness of the model. LASSO regression identified key biomarkers, and a nomogram was used to construct the score. The frailty index (FI) and all-cause mortality were used as the outcomes, and the score's predictive ability was evaluated using ROC curves, C-index and decision curve analysis. Subgroup analyses were conducted to assess the score's consistency across age, sex and clinical conditions.
resultsSixteen haematological markers were selected through LASSO regression. The nomogram demonstrated that a scoring model based on cystatin C and creatinine can achieve optimal predictive performance. The Cystatin C-Creatinine Score demonstrated strong predictive power for frailty (AUC = 0.687) and all-cause mortality (AUC = 0.733). Logistic regression analysis showed a significant association between higher Cystatin C-Creatinine Scores and increased frailty risk, with participants in the high-risk group having an OR of 1.48 (95% CI: 1.35-1.62, p < 0.001) compared to the low-risk group. Cox proportional hazards models also indicated that higher scores were associated with increased mortality risk (HR = 3.34, 95% CI: 1.75-6.38, p < 0.001 for the high-risk group). In the validation set, the AUC values of the Cystatin C-Creatinine Score for predicting frailty and all-cause mortality reached 0.701 and 0.713, respectively.
conclusionOur findings support the use of the Cystatin C-Creatinine Score as a practical and effective tool for identifying individuals at higher risk of frailty and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.